Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...

Bristol-Myers Squibb Co (NYSE:BMY) shares are trading higher Monday. The stock appears to be reacting positively after AbbVie ...

Shares of Bristol Myers Squibb Co. BMY shed 1.34% to $59.02 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.29% to 5,983.99 ...

Bristol Myers Squibb (NYSE: BMY) recently reported its Q3 results, with revenues and earnings exceeding the street estimates. It reported revenue of $11.9 billion and adjusted earnings of $1.80 ...

Bristol Myers Squibb had its Relative Strength (RS) Rating upgraded from 63 to 79 Tuesday — a welcome improvement, but still ...

AbbVie said it was disappointed with the results of its emraclidine trial for treating schizophrenia Bristol Myers Squibb Co. shares surged on Monday after rival AbbVie Inc. reported disappointing ...

Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of ...

Bristol Myers Squibb (BMY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

PRINCETON, N.J., November 05, 2024--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in two upcoming investor conferences in November 2024.

David Risinger, an analyst from Leerink Partners, maintained the Hold rating on Bristol-Myers Squibb (BMY – Research Report). The associated price target was raised to $55.00. David Risinger has ...

Okay. So, in the interest of staying on time here, really pleased to have Bristol Myers Squibb joining us. To my immediate right is Samit Hirawat. He is the Chief Medical Officer and Head of ...